Repository logo
 

Insights from multi-omic modeling of neurodegeneration in xeroderma pigmentosum using an induced pluripotent stem cell system.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Momen, Sophie 
Koh, Gene Ching Chiek 
Boushaki, Soraya 
Roumeliotis, Theodoros I 

Abstract

Xeroderma pigmentosum (XP) is caused by defective nucleotide excision repair of DNA damage. This results in hypersensitivity to ultraviolet light and increased skin cancer risk, as sunlight-induced photoproducts remain unrepaired. However, many XP patients also display early-onset neurodegeneration, which leads to premature death. The mechanism of neurodegeneration is unknown. Here, we investigate XP neurodegeneration using pluripotent stem cells derived from XP patients and healthy relatives, performing functional multi-omics on samples during neuronal differentiation. We show substantially increased levels of 5',8-cyclopurine and 8-oxopurine in XP neuronal DNA secondary to marked oxidative stress. Furthermore, we find that the endoplasmic reticulum stress response is upregulated and reversal of the mutant genotype is associated with phenotypic rescue. Critically, XP neurons exhibit inappropriate downregulation of the protein clearance ubiquitin-proteasome system (UPS). Chemical enhancement of UPS activity in XP neuronal models improves phenotypes, albeit inadequately. Although more work is required, this study presents insights with intervention potential.

Description

Keywords

CP: Cell biology, CP: Neuroscience, DNA damage, UPS, XP, early detection, endoplasmic reticulum stress response, iPSCs, neurodegeneration, oxidative stress, ubiquitin-proteasome system, xeroderma pigmentosum, Xeroderma Pigmentosum, Induced Pluripotent Stem Cells, Humans, Neurons, Oxidative Stress, Endoplasmic Reticulum Stress, Proteasome Endopeptidase Complex, Cell Differentiation, DNA Damage, Models, Biological, Multiomics

Journal Title

Cell Rep

Conference Name

Journal ISSN

2211-1247
2211-1247

Volume Title

Publisher

Elsevier BV
Sponsorship
Gray Foundation (via Massachusetts General Hospital) (235599)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC4 Y1)
Dr. Josef Steiner Cancer Foundation (Award 2019)
Cancer Research UK (23916)
Cancer Research UK (C60100/A27815)
Medical Research Council (MR/R015724/1)
Cancer Research UK (23433)
Cancer Research UK (A27453)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Fundings: SM was funded by a Wellcome PhD fellowship WT216339/Z/19/Z. This work was supported by Cancer Research UK (CRUK) Advanced Clinician Scientist Award (C60100/A23916), Dr Josef Steiner Cancer Research Award 2019, Basser Gray Prime Award 2020, CRUK Pioneer Award (C60100/A23433), CRUK Grand Challenge Award (C60100/A25274), CRUK Early Detection Project Award (C60100/A27815), and the National Institute of Health Research (NIHR) Research Professorship (NIHR301627). This work was also supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The work of T.I.R and J.S.C was funded by the CRUK Centre grant with reference number C309/A25144. L.V.-J. was supported by the long-term FEBS fellowship and by the CRUK Programme Foundation award to C.F. (C51061/A27453).